RESULTS

The combination of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer (Mol. Clin. Oncol., 3, 563-571, 2014.)

Metabolism may determine the biologically malignant behavior of pancreatic cancer. To investigate the significance and prognostic value of cancer metabolism in cancer patients, Ogawa et al.,  in collaboration with the Department of Surgery, Osaka University,  investigated the expression of two key enzymes in anaerobic glycolysis, hexokinase 2 (HK2) and pyruvate kinase isoenzyme type M2  (PKM2). The results demonstrated that the expression of HK2 and PKM2, particularly their combination may predict an unfavorable clinical outcome in patients with pancreatic cancer.